Nephrogenic fibrosing dermopathy

TheScientificWorldJournal

Volumn 8, Issue , 2008, Pages 164-165

  Dhungel, Ashish ^a   Lattupalli, Rakesh ^a   Topf, Joel ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Dialysis; Gadolinium; Nephrogenic fibrosing dermopathy

Indexed keywords

GADOLINIUM;

ADULT; ANKLE; ARTICLE; CASE REPORT; CELL PROLIFERATION; DISEASE COURSE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IMMOBILIZATION; KIDNEY FAILURE; KIDNEY INJURY; KNEE; LEG; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SCLERODERMA; SKIN BIOPSY; SKIN TIGHTNESS;

CONTRAST MEDIA; FEMALE; GADOLINIUM; GRAFT REJECTION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; SKIN DISEASES;

EID: 39449100288     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2008.28     Document Type: Article

References (2)

1. Cowper, S.E., Su, L., Robin, H., Bhawan, J., and LeBoit, P.E. (2001) Nephrogenic fibrosing dermopathy. Am. J. Dermatopathol. 23, 383-393.
2. http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm [U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Public Health Advisory. Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy.